Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660567 | 1.00 | CYP2C9 (0.34) | CYP2C9CYP3A4CYP2C19ERN1CES2 | |
| SCHEMBL11992946 | 0.82 | CYP2C9 (0.41) | CYP2C9CYP3A4CYP2C19ERN1CYP2D6 | |
| SCHEMBL415893 | 0.80 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19ERN1CES2 | |
| SCHEMBL31685229 | 0.80 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19ERN1CES2 | |
| SCHEMBL16825605 | 0.78 | ERN1 (0.31) | ERN1 | |
| SCHEMBL16936373 | 0.78 | ERN1 (0.34) | ERN1 | |
| SCHEMBL15273920 | 0.78 | MEN1 (0.37) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL31035827 | 0.78 | ERN1 (0.34) | ERN1 | |
| SCHEMBL6723791 | 0.75 | KIF11 (0.39) | CYP2C9CYP2D6 | |
| SCHEMBL1816745 | 0.74 | ERN1 (0.43) | CYP2C9CYP3A4CYP2C19ERN1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| US-6811832-B2 | AGROCHEMICALS, ELECTRONICS, DRUGS | CLARIANT GMBH (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20010050352-A1 | Agrochemicals, electronics, drugs | CLARIANT GMBH | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | CYP2C9 830/4885CYP3A4 2616/4885CYP2C19 1987/4885 |
| US-20010050352-A1 | Agrochemicals, electronics, drugs | AFF1, FPR1, CYP2F1 | CYP2C9 38/4885CYP3A4 117/4885CYP2C19 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.